SureTrader
Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Holy shit! Wow, FDA hires Grail Sipes, former

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Biobillionair Member Profile
 
Followed By 69
Posts 11,093
Boards Moderated 0
Alias Born 01/12/13
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/17/2018 5:59:57 PM
Amarin Announces Commencement of VASCEPA® Clinical Development in Mainland China "GlobeNewswire Inc." - 1/17/2018 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/16/2018 6:01:23 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/9/2018 6:01:35 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/4/2018 4:57:25 PM
Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook "GlobeNewswire Inc." - 1/4/2018 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/2/2018 4:34:20 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/2/2018 4:33:51 PM
Amended Statement of Beneficial Ownership (3/a) "Edgar (US Regulatory)" - 12/22/2017 4:13:13 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 12/21/2017 4:04:15 PM
Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018 "GlobeNewswire Inc." - 12/19/2017 6:00:00 AM
Amarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco "GlobeNewswire Inc." - 12/18/2017 4:30:00 PM
Amended Statement of Changes in Beneficial Ownership (4/a) "Edgar (US Regulatory)" - 12/4/2017 4:48:02 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/4/2017 9:04:12 AM
Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular ... "GlobeNewswire Inc." - 11/14/2017 4:30:00 PM
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Pat... "GlobeNewswire Inc." - 11/13/2017 4:30:00 PM
Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical ... "GlobeNewswire Inc." - 11/13/2017 6:00:00 AM
Amarin to Present at the Jefferies London Healthcare Conference "GlobeNewswire Inc." - 11/7/2017 6:00:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/1/2017 6:35:17 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/1/2017 6:31:37 AM
Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations "GlobeNewswire Inc." - 11/1/2017 5:30:00 AM
Amarin to Report Third Quarter 2017 Results and Host Conference Call on November 1, 2017 "GlobeNewswire Inc." - 10/25/2017 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/6/2017 7:23:03 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:26:27 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:26:02 PM
Biobillionair   Friday, 10/31/14 10:55:20 PM
Re: None
Post # of 121134 
Holy shit! Wow, FDA hires Grail Sipes, former partner at Covington's, as CDER policy director. Definitely a sign!
New CDER Compliance Director is from DOJ

Office of Regulatory Policy
Director
Grail Sipes, J.D.
(DKKNAA)

Grail wife of Christopher Sipes, attorney who represent Amarin at June OB meeting and NCE suit !!!


Kurt R. Karst, Robert Dormer, Josephine Torrente (Hyman, Phelps & McNamara); Joseph Kennedy, Steven Ketchum, Peggy Berry, Paresh Soni, Barbara Kurys (Amarin); Christopher Sipes (Covington & Burling)


http://www.fda.gov/AboutFDA/CentersOffices/OrganizationCharts/ucm184745.htm

Office of Compliance
Director
Cynthia Schnedar


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist